Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.
Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. Journal Of Clinical Oncology 2002, 20: 142-52. PMID: 11773163, PMCID: PMC2064865, DOI: 10.1200/jco.2002.20.1.142.Peer-Reviewed Original ResearchConceptsDose-related toxicityMetastatic melanomaAntitumor effectsTumor colonizationMetastatic renal cell carcinomaTumor necrosis factor alphaPhase IPresent phase IMaximum-tolerated doseObjective tumor regressionIntravenous bolus infusionAttenuated Salmonella typhimuriumDose-related increaseElevated alkaline phosphataseNecrosis factor alphaRenal cell carcinomaSalmonella typhimuriumPersistent bacteremiaIL-12Proinflammatory cytokinesCell carcinomaIL-6Intravenous infusionBolus infusionTumor regression